In a groundbreaking revelation, the Global Antidiabetics Industry is on the brink of unparalleled growth, poised to achieve a remarkable milestone by reaching an impressive US$ 89.2 billion in 2022. This substantial surge, reflecting a robust year-on-year growth rate of 10.9%, underscores the industry’s resilience and vitality. The journey doesn’t end there – industry analysts …